Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Adams

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
The Journal of Clinical Endocrinology and Metabolism|February 5, 2020
AMH is Higher Across the Menstrual Cycle in Early Postmenarchal Girls than in Ovulatory WomenMadison T Ortega, Lauren Carlson, John A McGrath, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2007
Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitorsRonghui Lin, George Chiu, Yang Yu, et al.
Journal of Community Genetics|July 18, 2019
Exploring perceptions of consanguineous unions with women from an East London community: analysis of discussion groupsMeghan A Cupp, Mary Adams, Michelle Heys, et al.
Archives of Neurology|December 10, 2008
Communicating clinical trial results to research participantsE Ray Dorsey, Christopher A Beck, Mary Adams, et al.
Arthritis Research & Therapy|August 18, 2022
CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine productionRajula Gaur, Kofi A Mensah, Jason Stricker, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2007
Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1)Shenlin Huang, Ronghua Li, Peter J Connolly, et al.
Rheumatology and Therapy|November 14, 2019
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic StudyPeter H Schafer, Alan J Kivitz, Jianglin Ma, et al.
Clinical Pharmacology in Drug Development|June 28, 2023
Safety, Pharmacokinetics, and Antifibrotic Activity of CC-90001 (BMS-986360), a c-Jun N-Terminal Kinase Inhibitor, in Pulmonary FibrosisGerald Horan, Ying Ye, Mary Adams, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2008
A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: design, synthesis, and biological activityTerry V Hughes, Guozhang Xu, Steven K Wetter, et al.
Bioorganic & Medicinal Chemistry Letters|March 17, 2009
Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsRonghui Lin, Sigmond G Johnson, Peter J Connolly, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
The Journal of Clinical Endocrinology and Metabolism|February 5, 2020
AMH is Higher Across the Menstrual Cycle in Early Postmenarchal Girls than in Ovulatory WomenMadison T Ortega, Lauren Carlson, John A McGrath, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2007
Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitorsRonghui Lin, George Chiu, Yang Yu, et al.
Journal of Community Genetics|July 18, 2019
Exploring perceptions of consanguineous unions with women from an East London community: analysis of discussion groupsMeghan A Cupp, Mary Adams, Michelle Heys, et al.
Archives of Neurology|December 10, 2008
Communicating clinical trial results to research participantsE Ray Dorsey, Christopher A Beck, Mary Adams, et al.
Arthritis Research & Therapy|August 18, 2022
CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine productionRajula Gaur, Kofi A Mensah, Jason Stricker, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2007
Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1)Shenlin Huang, Ronghua Li, Peter J Connolly, et al.
Rheumatology and Therapy|November 14, 2019
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic StudyPeter H Schafer, Alan J Kivitz, Jianglin Ma, et al.
Clinical Pharmacology in Drug Development|June 28, 2023
Safety, Pharmacokinetics, and Antifibrotic Activity of CC-90001 (BMS-986360), a c-Jun N-Terminal Kinase Inhibitor, in Pulmonary FibrosisGerald Horan, Ying Ye, Mary Adams, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2008
A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: design, synthesis, and biological activityTerry V Hughes, Guozhang Xu, Steven K Wetter, et al.
Bioorganic & Medicinal Chemistry Letters|March 17, 2009
Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsRonghui Lin, Sigmond G Johnson, Peter J Connolly, et al.
Pageof 6